You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firms will present a clinical comparison study using the workflow to detect FGFR mutations in 50 urothelial cancer patients later this year.
The company plans to publish new data on clinical sensitivity and specificity and has initiated multiple studies investigating new use cases.
The partners will commercialize a line of oncology mutation panels on the Stilla Naica digital PCR system.
Qiagen said that growth in the quarter was primarily driven by COVID-19 testing products and improving customer demand for other products.
The assay, called the single telomere absolute-length rapid (STAR) assay, uses Fluidigm microfluidic chips and was found to be accurate and sensitive.
JPM moved to an Overweight rating on both companies from a Not Rated designation assigned during a restriction period as Thermo Fisher's potential acquisition of Qiagen played out.
While new ways to carry out pool testing for SARS-CoV-2 abound, questions remain about sensitivity issues and the regulation of such tests.
The launch of the company's Prism system earlier this month should support the development of an accompanying menu of tests to serve diverse users.
The firm's Continuum system is fully automated and performs the entire digital PCR workflow in a single instrument.
In PLOS this week: computational strategy to study human population histories, BRAF mutational load in melanoma and disease progression, and more.
NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.
Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.
Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.
In Science this week: review discusses advances in liquid biopsies, and more.